Tata Consultancy Services (TCS) is currently trading at Rs. 2181.45, up by 7.45 points or 0.34% from its previous closing of Rs. 2179.90 on the BSE.
The scrip opened at Rs. 2179.90 and has touched a high and low of Rs. 2194.70 and Rs. 2166.40 respectively. So far 102621 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 2290.65 on 21-Jun-2019 and a 52 week low of Rs. 1784.00 on 29-Oct-2018.
Last one week high and low of the scrip stood at Rs. 2217.00 and Rs. 2103.60 respectively. The current market cap of the company is Rs. 821321.96 crore.
The promoters holding in the company stood at 72.05%, while Institutions and Non-Institutions held 23.81% and 4.15% respectively.
Tata Consultancy Services (TCS) has launched the Advanced Drug Development (ADD) Site Feasibility Platform, which provides life sciences companies with a single, integrated platform that digitizes the site selection and activation processes, and facilitates data-driven decision-making while assessing site feasibility for multi-site clinical trials.
TCS’ Site Feasibility Platform, the latest addition to the ADD suite of cloud-based clinical platforms, addresses this critical problem currently faced by life sciences companies, by leveraging the power of digital technologies to drive superior clinical outcomes.
Moreover, the platform is fully integrated with the TCS Connected Clinical Trials e-Survey Platform, providing customers with an end-to-end solution for conducting site surveys and analyzing the survey responses.
Tata Consultancy Services is an IT services, consulting and business solutions provider that has been partnering with the world’s largest businesses in their transformation journeys for the last fifty years.